Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3.
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2013
At a glance
- Drugs Masitinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- 19 Oct 2011 Status changed from active, no longer recruiting to completed.
- 17 Oct 2011 Results have been presented in an AB Science media release.
- 27 Mar 2009 New trial record